Preclinical and clinical evidence suggested that intranasal insulin improves memory function (Badenes et al., 2021) and can also improve functional performance in patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD) (Claxton et al., 2015; Novak et al., 2019). This evidence concerns the gene INS and Parkinson disease.